Perforomist is a drug owned by Mylan Specialty Lp. It is protected by 6 US drug patents filed from 2013 to 2018 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jun 22, 2021. Details of Perforomist's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US7462645 | Bronchodilating beta-agonist compositions and methods |
Jun, 2021
(3 years ago) |
Expired
|
| US9730890 | Bronchodilating beta-agonist compositions and methods |
Jun, 2021
(3 years ago) |
Expired
|
| US6814953 | Bronchodilating compositions and methods |
Jun, 2021
(3 years ago) |
Expired
|
| US8623922 | Bronchodilating Beta-agonist compositions and methods |
Jun, 2021
(3 years ago) |
Expired
|
| US7348362 | Bronchodilating β-agonist compositions and methods |
Jun, 2021
(3 years ago) |
Expired
|
| US6667344 | Bronchodilating compositions and methods |
Jun, 2021
(3 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Perforomist's patents.
Latest Legal Activities on Perforomist's Patents
Given below is the list of recent legal activities going on the following patents of Perforomist.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical | 20 Sep, 2021 | US9730890 |
| Maintenance Fee Reminder Mailed Critical | 05 Apr, 2021 | US9730890 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 02 Jun, 2020 | US7462645 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 18 Sep, 2019 | US7348362 |
| Patent Issue Date Used in PTA Calculation Critical | 15 Aug, 2017 | US9730890 |
| Recordation of Patent Grant Mailed Critical | 15 Aug, 2017 | US9730890 |
| Issue Notification Mailed Critical | 26 Jul, 2017 | US9730890 |
| Dispatch to FDC | 19 Jul, 2017 | US9730890 |
| Filing Receipt - Corrected | 19 Jul, 2017 | US9730890 |
| Record Petition Decision of Granted to Accept Delayed Payment of Issue Fee | 11 Jul, 2017 | US9730890 |
US patents provide insights into the exclusivity only within the United States, but Perforomist is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Perforomist's family patents as well as insights into ongoing legal events on those patents.
Perforomist's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Perforomist's generic launch date based on the expiry of its last outstanding patent is estimated to be Jun 22, 2021 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Perforomist Generic API suppliers:
Formoterol Fumarate is the generic name for the brand Perforomist. 8 different companies have already filed for the generic of Perforomist, with Alembic having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Perforomist's generic
How can I launch a generic of Perforomist before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Perforomist's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Perforomist's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Perforomist -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 0.02 mg/2 mL | 21 Jan, 2009 | 1 | 22 Jun, 2021 | Extinguished |
Alternative Brands for Perforomist
Perforomist which is used for managing bronchoconstriction in patients with COPD., has several other brand drugs using the same active ingredient (Formoterol Fumarate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |||
|---|---|---|---|---|
| Astrazeneca |
| |||
| Astrazeneca Ab |
| |||
| Covis |
| |||
| Novartis |
| |||
| Organon Llc |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Formoterol Fumarate, Perforomist's active ingredient. Check the complete list of approved generic manufacturers for Perforomist
About Perforomist
Perforomist is a drug owned by Mylan Specialty Lp. It is used for managing bronchoconstriction in patients with COPD. Perforomist uses Formoterol Fumarate as an active ingredient. Perforomist was launched by Mylan Speclt in 2007.
Approval Date:
Perforomist was approved by FDA for market use on 11 May, 2007.
Active Ingredient:
Perforomist uses Formoterol Fumarate as the active ingredient. Check out other Drugs and Companies using Formoterol Fumarate ingredient
Treatment:
Perforomist is used for managing bronchoconstriction in patients with COPD.
Dosage:
Perforomist is available in solution form for inhalation use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.02MG/2ML | SOLUTION | Prescription | INHALATION |